Navigation Links
Psoriasis in Biological Technology

Raptiva Withdrawal Offers Upside for Enbrel and Humira According to Latest BioTrends Survey of U.S. Dermatologists

... syndicated report TreatmentTrends (R) : psoriasis , the fourth annual survey of U.S. ... highlights shifting trends in the management of psoriasis and psoriatic arthritis. This comprehensive ... use of biologic agents. The vast majority of psoriasis patients across all disease severity categories ...

Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

... with inflamed, scaly, red patches of skin psoriasis and psoriasis nail involvement. Symptoms may include ... feet, lower back and neck are commonly affected. psoriasis affects an estimated two to three percent of the ...

Latest BioTrends Research Reports to Assess the Impact of the Withdrawal of Raptiva (efalizumab) on the Psoriasis Market

... field its fourth annual TreatmentTrends(TM): psoriasis survey on April 13th with a special section ... by BioTrends, ChartTrends(TM): Biologics in psoriasis , is a report that is based on actual patient ... According to last year's TreatmentTrends(TM): psoriasis report, market share for Raptiva had steadily ...

Photos: 'Project Runway's' Tim Gunn Launches Addressing Psoriasis(TM) Campaign to Advocate That Patients Shouldn't Let Psoriasis Impact Personal Style

... campaign designed to help people with plaque psoriasis get more information about managing their disease ... working together to encourage people with plaque psoriasis to visit a dermatologist and take the first step ... people who have moderate to severe plaque psoriasis but who try not to allow the condition to inhibit ...

New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis

... is for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a ... adults living with moderate-to-severe plaque psoriasis a new therapy which has the potential to make a ... in the treatment of moderate-to-severe plaque psoriasis were evaluated.(4,5) Two-thirds or more of ...

One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study

... in physical function and arthritis and psoriasis components of the disease. These findings were ... than 3 percent Body Surface Area (BSA) psoriasis skin involvement at baseline were evaluated for ... and enthesitis, as measured by the Nail psoriasis Severity Index (NAPSI) and the psoriatic ...

Dermatologists Report Increased Use of Biologics in the Treatment of Psoriasis

... its third annual TreatmentTrends (TM): psoriasis publication, providing insight into the ... in their use of biologics for the treatment of psoriasis in the past year, particularly in patients with ... While the use of oral agents to treat psoriasis increases with disease severity, less ...

Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

... with inflamed, scaly, red patches of skin psoriasis and psoriasis nail involvement. Symptoms may include stiffness ... feet, lower back and neck are commonly affected. psoriasis affects an estimated two to three percent of the ...

NeoStrata(R) Announces the Launch of PSORENT(TM) Psoriasis Topical Treatment

... distillate), which has proven efficacy against psoriasis symptoms, in a novel, aesthetically advanced ... physicians will be able to offer patients a novel psoriasis treatment that reduces the unpleasant aspects ... first-line therapy for the vast majority of psoriasis patients." PSORENT is an aesthetically ...

Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA

... percent reduction in psoriasis as measured by the psoriasis Area and Severity Index (PASI 75). Acceptance of ... past Saturday, February 2. About Psoriasis psoriasis is a chronic, immune-mediated disease, which ... from debilitating immune disorders. 1. National psoriasis Foundation. About Psoriasis: ...

Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis

... is an established target for drug development in psoriasis and other autoimmune diseases. The effectiveness ... a planned Phase 2 clinical trial for plaque psoriasis beginning mid-2008, pending approval from the ... in the fourth quarter of 2008. We expect this psoriasis program will help to expand our product portfolio ...

Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis

... treatment of moderate to severe plaque psoriasis. psoriasis will be the fifth disease indication for HUMIRA. psoriasis is a non-contagious, chronic autoimmune disease ... known as plaques, which may crack and bleed. But psoriasis is more than painful skin lesions; data also ...

Specialists Are Turning to Biologics Earlier in the Treatment of Psoriasis and Psoriatic Arthritis

... biologics earlier in the course of treatment for psoriasis and psoriatic arthritis. According to the new Physician & Payer Forum report entitled psoriasis and Psoriatic Arthritis: The Expanding Biologics ... tried an average of 5.8 therapies for moderate psoriasis before turning to biologics. By mid-2008 they ...

avVaa World Health Care Products Inc. Announces Web Site Design for Neuroskin(R) Psoriasis Relief DRTV Campaign

... official site, which will be named at a later date include NEUROSKIN(R) psoriasis Relief, NEUROSKIN(R)Acne Treatment, NEUROSKIN(R) Itch Relief and ... relieve and treat the symptoms of common skin ailments, including: eczema, psoriasis and acne. avVaa is poised to manufacture and market its OTC Neuroskin(R) ...

BioCis Pharma Starts Phase IIa Trial in Psoriasis

... expect to get results from both studies by third quarter of 2009." psoriasis is an immune-mediated chronic inflammatory disease characterized by local ... about 2 to 3 per cent of the general population in the Western countries. psoriasis may significantly impair the life quality of the affected subjects, and it ...

FDA Extends Review Timeline for Ustekinumab Biologic License Application Three Months

... under review by the European Medicines Agency (EMEA). About Psoriasis psoriasis is a chronic, immune-mediated disease, which results from ... people in the United States and 10 million Europeans are living with psoriasis and nearly one-quarter of those people have cases that are considered ...

BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008

... commercialization including forodesine HCl in oncology, BCX-4208 in psoriasis and peramivir in seasonal and life-threatening influenza. BioCryst is ... (CTCL) may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization ...

William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals

... commercialization including forodesine HCl in oncology, BCX-4208 in psoriasis and peramivir in seasonal and life-threatening influenza. BioCryst is ... (CTCL) may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization ...

BioCryst Reports First Quarter 2008 Financial Results and Clinical Update

... commercialization including forodesine HCl in oncology, BCX-4208 in psoriasis and peramivir in seasonal and life-threatening influenza. BioCryst is ... (CTCL) may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization ...

Biologics, Derma Fillers are Key to Dermatological Drug Market Growth

... "There are impressive new options for the treatment of aging skin, acne, psoriasis and a host of other conditions -- including bio-engineered collagen, ... for the development of new agents. Biologics are expected to dominate the psoriasis market with a 70% market share by 2011, due to the introduction of several ...

Centocor/Janssen-Cilag's Ustekinumab Will Become the Gold Standard for Psoriasis By 2011

... ustekinumab will become the clinical gold standard for psoriasis by 2011. Ustekinumab will achieve gold standard status because of its ... is the attribute that most influences their prescribing decisions in psoriasis and clinical data shows that ustekinumab has advantages over sales-leading ...

REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide

... of adults with chronic, severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies ... is also approved in the EU for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or have a contraindication to, or are ...

R-Tech Ueno Notifies R&D Items

... an unconventional action, VAP-1* inhibition. We intend to develop this compound as a drug indicated for atopic dermatitis, contact dermatitis and psoriasis vulgaris in the dermatological field, and diabetic neuropathy in the neurological field. We plan to report on the development status of each ...

avVaa World Health Care Products, Inc. Signs Agreement with 3PL Worldwide, Inc., for Order Management & Fulfillment for avVaa's Product

... are scientifically registered, FDA-Compliant, and were developed to relieve and treat the symptoms of common skin ailments, including eczema, psoriasis and acne. avVaa is poised to manufacture and market its OTC Neuroskin(r) line of skin care products through mass, food and drug channels in the ...

avVaa World Health Care Products, Inc. Announces Engagement of Koeppel Direct for their DRTV-Direct Response Television Media Buying Campaign

... are scientifically registered, FDA-Compliant, and were developed to relieve and treat the symptoms of common skin ailments, including eczema, psoriasis and acne. avVaa is poised to manufacture and market its OTC Neuroskin(r) line of skin care products through mass, food and drug channels in the ...

Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma

... agent that works by inhibiting DNA replication. Nitrogen mustard has also demonstrated activity in other T-cell proliferating diseases such as psoriasis and alopecia areata and has a rich history of use in dermatology dating back to the 1950s. To date, topical nitrogen mustard has only been available ...

NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBay's Novel Aganocide Drugs for Major Dermatological Conditions

... medical, corrective and aesthetic solutions to treat a range of dermatological conditions including: acne, rosacea, fungal nail infections, psoriasis & other steroid-responsive dermatoses, pigmentary disorders, skin cancer and medical solutions for skin senescence. Galderma has research and ...

Rigel Announces Third Quarter 2008 Financial Results and Clinical Update

... future collaboration partner for R788 to jointly evaluate this indication and decide how to proceed. R348 Moving forward, Rigel plans to focus on psoriasis and possible topical applications with its Jak3 inhibitor, R348, and to do so with a collaboration partner. Rigel will move forward with another ...

BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update

... meeting. -- BioCryst reported top-line results from the completed Phase 2a trial of BCX-4208 in subjects with moderate to severe plaque psoriasis were consistent with interim findings. BCX-4208, a potent, rationally designed, orally available purine nucleoside phosphorylase ...

MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology

... (SLE) and a phase 1b study in patients with active dermatomyositis and polymyositis. The company has also conducted clinical trials in psoriasis with MEDI-545. -- CAM-3001 - CAM-3001 is a MAb with potential to help patients with rheumatoid arthritis. The antibody targets the alpha ...

Merck Serono Named as a Top Employer by Science Magazine

... infertility (Gonal-f(R)), endocrine and cardiometabolic disorders (Glucophage(R), Concor(R), Euthyrox(R), Saizen(R), Serostim(R)), as well as psoriasis (Raptiva(R)). With an annual R&D expenditure of around EUR 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic ...

BioCryst to Present at the JMP Healthcare Focus Conference

... that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees ...

Kuvan Receives Positive Opinion From CHMP for European Approval

... infertility (Gonal-f(R)), endocrine and cardiometabolic disorders (Glucophage(R), Concor(R), Euthyrox(R), Saizen(R), Serostim(R)), as well as psoriasis (Raptiva(R)). With an annual R&D expenditure of around euro 1bn, Merck Serono is committed to growing its business in specialist-focused ...

BioCryst to Present at UBS 2008 Global Life Sciences Conference

... that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees ...

GlaxoSmithKline and Cellzome Announce Major Strategic Alliance

... such as PI3Kg and d, Zap-70, Jak3 and mTOR, as potential oral therapeutics for rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis and asthma. In addition to the GSK collaboration, Cellzome has an alliance with Johnson & Johnson focused on the discovery of novel medicines for ...

Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award

... VBL has developed a new family of anti-inflammatory drugs for chronic inflammatory diseases, such as Rheumatoid Arthritis, Multiple Sclerosis, psoriasis and Inflammatory Bowel Disease. VBL has also developed the Vascular Targeting System (VTSTM), a new platform technology targeting the formation of ...

Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs

... we intend to initiate clinical development for the treatment of rheumatoid arthritis in early 2009; and our JAK3 program for the topical treatment of psoriasis which we expect to enter preclinical development in 2009. Discovery research remains a core strength of Pharmacopeia and will be increasingly focused ...

Abbott Annual Meeting Highlights Outstanding 2007 Results, International Growth and Near-Term Pipeline

... in 2008: -- Already in 2008, the company has introduced two new indications for HUMIRA(R) (adalimumab) -- moderate to severe plaque psoriasis and moderate to severely active polyarticular juvenile idiopathic arthritis, both of which received U.S. Food and Drug Administration ...

Galderma Completes Acquisition of CollaGenex

... health of skin with an extensive line of products that treat a range of dermatological conditions including: acne, rosacea, fungal nail infections, psoriasis & steroid-responsive dermatoses, pigmentary disorders, medical solutions for skin senescence and skin cancers. With a research and development center ...

BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update

... that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees ...
Other Contents
(Date:1/22/2015)... FindBiometrics, the leading source of biometrics industry news, interviews and ... "When we launched FindBiometrics 12 years ago the ... founder and CEO of FindBiometrics. "Now it,s maturing very quickly. ... players on a very broad scale.  We are known for ...
(Date:1/22/2015)... 2015 Technology Showcase, Hall E -   EyeLock Inc. ... announced it will showcase its EyeLock ID technology integrated in ... of Energy,s Oak Ridge National Laboratory (ORNL) at ... iris identity authentication technology is being used to validate the ...
(Date:1/22/2015)... , Jan. 16, 2015  A man-made form of insulin ... other mental capabilities in adults with mild cognitive impairment ... led by researchers at Wake Forest Baptist Medical Center. ... with amnesic mild cognitive impairment (MCI) or mild to ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put ... muscle by up to 30lbs in less than 12 weeks ... Stan Stevenson, prompting an investigative review. , “Our Incredible ... diet formula that allows the body to pack on a ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Blue Cross and ... Minnesotans who exemplify what it means to “Live Fearless.” ... for people to share their stories about how they or ... simply inspired others by living in the moment. By telling ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
(Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post ... insurance policy . , Auto insurance quotes help many ... no longer necessary to call an agent or visit an ... on a single website: http://autocarinsurancebest.com/ . , Every business ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2
Other TagsOther Tags